Corinne Le Goff's most recent trade in Viatris Inc was a trade of 39,344 Common Stock done . Disclosure was reported to the exchange on April 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 39,344 | 60,441 (0%) | 0% | 0 | Common Stock | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 39,344 | 39,344 | - | - | Restricted Stock Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.48 per share. | 15 Apr 2025 | 19,023 | 41,418 (0%) | 0% | 7.5 | 142,292 | Common Stock |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 1,768 | 43,186 (0%) | 0% | 0 | Common Stock | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 1,767 | 1,768 | - | - | Dividend Equivalent Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.48 per share. | 15 Apr 2025 | 855 | 42,331 (0%) | 0% | 7.5 | 6,395 | Common Stock |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 132,493 | 132,493 | - | - | Restricted Stock Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 36,721 | 73,441 | - | - | Restricted Stock Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 36,721 | 36,721 (0%) | 0% | 0 | Common Stock | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.37 per share. | 04 Mar 2025 | 16,276 | 20,445 (0%) | 0% | 9.4 | 152,506 | Common Stock |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 1,173 | 21,618 (0%) | 0% | 0 | Common Stock | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 1,172 | 2,344 | - | - | Dividend Equivalent Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.37 per share. | 04 Mar 2025 | 521 | 21,097 (0%) | 0% | 9.4 | 4,882 | Common Stock |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 22,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 13,397 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 110,162 | 110,162 | - | - | Restricted Stock Units | |
| Viatris | Corinne Le Goff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 78,688 | 78,688 | - | - | Restricted Stock Units | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Imunon Inc | Corinne Le Goff | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 90,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Imunon Inc | Corinne Le Goff | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 177,000 | 177,000 | - | - | Stock Option (Right to Buy) | |
| Imunon Inc | Corinne Le Goff | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 53,000 | 53,000 (0%) | 0% | 0 | Common Stock | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 12,367 | 12,367 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 13,397 | 13,397 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Corinne Le Goff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 12,367 | 12,367 | - | - | Stock Option (Right to Buy) | |
| Moderna | Corinne Le Goff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 58,563 | 58,563 | - | - | Stock Option (Right to Buy) | |
| Moderna | Corinne Le Goff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 25,400 | 25,400 | - | - | Restricted Stock Units |